LYEL today
$16.86+$0.11 (+0.66%)close Nov 11, 2026Trend
DailyUptrend (starting)
4 hourStrong Bullish
1 hourLeaning Bearish
15 minBearish
5 minStrong Bullish
Daily trend turns down below $7.20
Key levels
Resistance$19.59
Resistance$17.15
Support$15.14
Support$13.39
Latest news & SEC filings
SEC FilingLyell Immunopharma, Inc. filed an insider trading report (Form 4)
DealLyell Immunopharma raises $80M through private sale of securities
ProductLyell Immunopharma to share new ronde-cel trial results at ASH 2026
EarningsLyell Immunopharma Posts Q3 2026 Financials
All LYEL news →About Lyell Immunopharma
Lyell Immunopharma is a clinical-stage biotechnology company that engineers a patient's own immune cells to fight cancer. Its main candidate, rondecabtagene autoleucel, is designed to attack lymphoma cells bearing two surface markers and is in late-stage testing. Another candidate, LYL273, targets colorectal tumors and is in early human studies. The company also works on therapies for other solid tumors and makes its products at a facility in Washington state.
Based on the company's 10-K filed Mar 12, 2026.
Nasdaq · Healthcare
Lyell Immunopharma, Inc. (LYEL)
What Is the Price Target for LYEL?
SEPT Low Target
$36.00
SEPT Mid Target
$44.00
SEPT High Target
$44.00
Analyst Consensus
$44.00
Is LYEL a Buy or Sell Right Now?
Thesis
- •Revenue growing -41.0% YoY with ACCELERATING trend — accelerating momentum.
- •SEC filings signal active product innovation — 1 new product/expansion keywords detected in 10-K. R&D investment stable.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for LYEL.
Start Free Trial →Is LYEL Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$39.43
25
Moat Score
NONE
1/9
Piotroski Score
-7.3
Altman Z-Score
What Is Smart Money Doing with LYEL?
Insider Signal
SELLING
2 buys / 12 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| ARCH Venture Partners IX, LLC | 10% owner | Buy | 2,321,262 | $25.0M | Nov 4, 2026 |
| ARCH Venture Fund XIII, L.P. | 10% owner | Buy | 2,321,262 | $25.0M | Nov 4, 2026 |
| Shook David | officer | Sale | 500 | $6K | Sep 10, 2026 |
| Shook David | officer | Sale | 1,977 | $25K | Jun 10, 2026 |
| Bulis Veronica Sanchez | officer | Sale | 217 | $4K | May 11, 2026 |
| Lee Gary K. | officer | Sale | 130 | $2K | May 11, 2026 |
| Hill Stephen J. | officer | Sale | 89 | $2K | May 11, 2026 |
| Seely Lynn | director officer | Sale | 388 | $7K | May 11, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →LYEL Growth Story
Revenue YoY
-41.0%
3yr Revenue CAGR
-92.5%
EPS Growth YoY
38.77%
FCF Growth YoY
7.4%
Revenue Trend
ACCELERATING
Dark Pool Trades for LYEL
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for LYEL, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 20:45:33 | $16.87 | 1,050 | $$18K | BUY |
| 19:16:10 | $17.10 | 1,500 | $$26K | SELL |
| 17:41:33 | $17.05 | 2,250 | $$38K | SELL |
| 16:47:23 | $17.39 | 1,415 | $$25K | BUY |
| 15:12:25 | $17.51 | 6,801 | $$119K | SELL |
5 dark pool trades shown · $$225K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Lyell Immunopharma, Inc. (LYEL) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →LYEL — frequently asked questions
What is LYEL stock price today?
Lyell Immunopharma, Inc. (LYEL) is at $16.86, up 0.66% (+$0.11) at the Nov 11, 2026 close.
Why is LYEL stock moving today?
Latest LYEL news — Nov 5, 2026: Lyell Immunopharma, Inc. filed an insider trading report (Form 4) · Nov 4, 2026: Lyell Immunopharma raises $80M through private sale of securities
What is the LYEL price target?
The average analyst price target for LYEL is $44.00, ranging from $36 to $44, based on 5 analysts.
What do analysts rate LYEL?
Analyst ratings for LYEL: 0 Buy, 12 Hold, 0 Sell — consensus Hold.
Did LYEL beat earnings?
LYEL last reported on Aug 6, 2026: EPS -$1.92 vs -$1.90 expected — a miss of 1.1%.
Does LYEL pay a dividend?
LYEL does not currently pay a dividend.
What are LYEL support and resistance levels?
Support: $15.14, $13.39, $10.56. Resistance: $17.15, $19.59, $21.55.
What are insiders doing with LYEL?
Insider activity: SELLING, 2 buys and 12 sells in the last 90 days.
What is the latest news on LYEL?
Nov 5, 2026: Lyell Immunopharma, Inc. filed an insider trading report (Form 4) · Nov 4, 2026: Lyell Immunopharma raises $80M through private sale of securities · Nov 4, 2026: Lyell Immunopharma to share new ronde-cel trial results at ASH 2026